IMR Press / EJGO / Volume 21 / Issue 4 / pii/2000204

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research

Comparison of endometrial pathologies collected by hysteroscopy and hysterectomy in postmenopausal breast cancer tamoxifen-treated patients

Show Less
1 Department of Obstetrics & Gynaecology, Kfar-Saba, affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel
2 Department of Pathology, Sapir Medical Center, Kfar-Saba, affiliated with Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel
Eur. J. Gynaecol. Oncol. 2000, 21(4), 418–422;
Published: 10 August 2000
Abstract

Purpose of investigation: 1) To assess whether endometrial specimens obtained from removed uteri might show an increase in endometrial pathologies which had been previously diagnosed by hysteroscopy in postmenopausal breast cancer tamoxifen-treated patients. 2) To assess whether hysteroscopy is an efficient method of detecting endometrial pathologies in such patients. Methods: The findings of two consecutive pathological evaluations in 18 postmenopausal breast cancer tamoxifen-treated patients, performed 11.2 ± 11.2 months apart, were compared. The first specimen was collected by hysteroscopy and the second was obtained following hysterectomy. Results: The most significant changes observed were three new cancers diagnosed at hysterectomy, one of which was poorly-dif­ferentiated. In the first (hysteroscopy) samplings, one patient had atrophic endometrium, a second patient had endometrial prolife­ration and a third patient had a benign endometrial polyp. Overall, 55.6% of the study patients had various endometrial pathologies in the first sampling, while 83.3% had endometrial pathologies in the second sampling. However, this difference was not statistically significant. Conclusion: 1) Endometrial histologic evaluations, performed on removed uteri 11.2 ± 11.2 months following previous endometrial samplings of postmenopausal breast cancer tamoxifen-treated patients, showed a non-significant risk of developing overall endometrial pathologies. 2) Hysteroscopy may have missed some endometrial pathologies which were diagnosed later on in specimens obtained by hysterectomy.

Keywords
Endometrial pathologies
Tamoxifen
Hysteroscopy and hysterectomy
Share
Back to top